
News|Articles|July 1, 2002
LABELING UPDATE: CLASS study, updated GI, CV risk info, added to celecoxib label
Safety information from the Celecoxib Long-term Arthritis Safety Study (CLASS)on GI and cardiovascular events has been included in safety labeling forcelecoxib (Celebrex, Searle).
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Positive results for Casgevy but with one patient death from myeloablative busulfan conditioning | ASH 2025
2
Quadruplet treatments for multiple myeloma are rising but access varies | ASH 2025
3
IV iron treatment improves survival, increases hemoglobin levels in anemic patients with acute bacterial infection | ASH 2025
4
AstraZeneca’s Imfinzi gains landmark FDA approval for early gastric and gastroesophageal cancers
5






















































